Phase 1 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who have been diagnosed with multiple myeloma that has come back or stopped responding to treatment, with up to 5 bone lesions that can be treated with radiation therapy, and whose bone lesions score within a certain safety range for spinal stability (confirm with trial site)
• People who have already received appropriate standard treatments, as determined by the treating doctor
• People who have at least one tumour that can be measured and is a suitable size for radiation treatment (roughly between a small grape and a large orange in volume)
• People who have a certain level of physical functioning, as rated by their doctor using a standard scale (an ECOG performance status of 2 or better) (confirm with trial site)
• People whose organ function — such as liver and kidney — meets acceptable levels based on blood test results, as confirmed by the study doctor
• Women of childbearing potential who have a negative pregnancy test taken within 72 hours before starting the study
• Women of childbearing potential who agree to use effective contraception during treatment and for 5 months after the last dose
• Men who are sexually active with women of childbearing potential and agree to use effective contraception during treatment and for 7 months after the last dose, and who agree to avoid donating sperm during that time
• People who are willing and able to attend scheduled visits, follow the treatment plan, and meet all other study requirements
• People who are able to give their own informed consent by signing a consent form approved by an ethics committee

Who may not be able to join:

• People whose bone lesion scores on the spinal instability or fracture risk scales fall outside the acceptable safety range for this trial (confirm with trial site)
• People who are currently receiving any other anti-myeloma or systemic treatment at the same time as the study (concurrent steroids are permitted)
• People who are still experiencing significant side effects from a previous treatment (generally above a mild level), with some exceptions for nerve-related side effects, hair loss, or recent surgery recovery — confirm details with trial site
• People who have previously received radiation to the area planned for treatment in this trial (if that prior radiation was less than 10% of the originally prescribed dose) (confirm with trial site)
• People who have received certain prior chemotherapy within 2 weeks, or certain prior antibody or targeted drug treatments within 7 days, of starting radiation
• People with another known cancer that could make it difficult to interpret the trial results, unless specifically approved by the lead researcher
• People with a known history of non-infectious lung inflammation that required steroid treatment
• People with evidence of a scarring or inflammatory lung disease
• People with a current seizure disorder
• People with a known psychiatric condition or substance use disorder that would make it difficult to follow the study requirements
• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial and up to 120 days after the last dose; men planning to father children during that same period
• People with known active Hepatitis B or Hepatitis C infection, if liver lesions are being considered for treatment
• People who have had a heart attack or stroke within the past 6 months, uncontrolled chest pain within the past 3 months, a history of certain serious heart rhythm problems, or other significant heart conditions
• People who require daily supplemental oxygen due to a heart or cardiovascular condition
• People currently taking statin medications, unless they have been on a stable dose for more than 3 months before the study and have not shown signs of muscle enzyme elevation (confirm with trial site)
• People with a current or past history of significant muscle disorders, recent unresolved muscle injury, or any condition known to raise a muscle enzyme called creatine kinase (CK)
• People who are currently imprisoned or held in a detention facility
• People who are under a legal order requiring them to receive psychiatric or medical treatment

Important: Always verify eligibility with the trial site directly before applying.